T1	Observation 0 10	MDD Cohort
T2	Qualifier 17 31	DSM-5 criteria
T3	Condition 36 61	Major Depressive Disorder
T4	Procedure 65 85	structured interview
T5	Procedure 87 95	MINI-KID
R2	Has_qualifier Arg1:T3 Arg2:T2	
R3	AND Arg1:T3 Arg2:T4	
T6	Measurement 98 110	CDRS-R score
T7	Value 111 114	>40
R4	Has_value Arg1:T6 Arg2:T7	
T8	Negation 116 123	Failure
T9	Condition 135 144	remission
T10	Multiplier 150 160	at least 1
T11	Qualifier 161 169	adequate
T12	Procedure 176 196	antidepressant trial
T13	Drug 203 207	SSRI
T14	Temporal 170 175	prior
T15	Drug 209 213	SNRI
T16	Drug 218 221	TCA
*	OR T16 T15 T13
T17	Scope 203 221	SSRI, SNRI, or TCA
R5	Has_temporal Arg1:T12 Arg2:T14	
R6	Has_qualifier Arg1:T12 Arg2:T11	
R7	Subsumes Arg1:T12 Arg2:T17	
R8	Has_multiplier Arg1:T12 Arg2:T10	
R9	Has_negation Arg1:T9 Arg2:T8	
T18	Multiplier 232 248	at least 8 weeks
T19	Procedure 252 270	therapeutic dosing
R11	Has_multiplier Arg1:T19 Arg2:T18	
T20	Multiplier 282 298	at least 4 weeks
T21	Procedure 302 315	stable dosing
R10	Has_multiplier Arg1:T21 Arg2:T20	
T22	Scope 232 315	at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing
T23	Scope 150 222	at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA)
R12	Has_scope Arg1:T23 Arg2:T22	
R13	Has_scope Arg1:T9 Arg2:T23	
T24	Observation 318 332	Anxiety Cohort
T25	Qualifier 339 353	DSM-5 criteria
T26	Condition 379 396	anxiety disorders
T27	Condition 398 422	Social Anxiety Disorders
T28	Condition 424 452	Generalized Anxiety Disorder
T29	Condition 454 481	Separation Anxiety Disorder
T30	Condition 489 503	Panic Disorder
T31	Procedure 507 527	structured interview
R1	Subsumes Arg1:T4 Arg2:T5	
T32	Procedure 529 537	MINI-KID
R14	Subsumes Arg1:T31 Arg2:T32	
*	OR T28 T29 T30 T27
T33	Scope 398 503	Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder
R15	AND Arg1:T33 Arg2:T31	
R16	Subsumes Arg1:T26 Arg2:T33	
T34	Measurement 540 569	ADIS Clinical Severity Rating
T35	Value 570 572	≥4
T36	Qualifier 574 591	moderately severe
R17	Has_value Arg1:T34 Arg2:T35	
T37	Scope 540 572	ADIS Clinical Severity Rating ≥4
R18	Subsumes Arg1:T37 Arg2:T36	
T38	Condition 619 636	anxiety disorders
T39	Condition 657 666	remission
T40	Negation 638 645	Failure
T41	Multiplier 672 682	at least 1
T42	Qualifier 683 691	adequate
T43	Temporal 692 697	prior
T44	Procedure 698 725	anxiolytic medication trial
T45	Drug 698 719	anxiolytic medication
R19	multi Arg1:T44 Arg2:T45	
T46	Drug 176 190	antidepressant
R20	multi Arg1:T12 Arg2:T46	
T47	Drug 732 736	SSRI
T48	Drug 738 742	SNRI
T49	Drug 747 750	TCA
*	OR T48 T49 T47
T50	Scope 732 750	SSRI, SNRI, or TCA
R21	Has_temporal Arg1:T44 Arg2:T43	
R22	Subsumes Arg1:T44 Arg2:T50	
R23	Has_qualifier Arg1:T44 Arg2:T42	
R24	Has_multiplier Arg1:T44 Arg2:T41	
R25	Has_negation Arg1:T39 Arg2:T40	
T51	Multiplier 761 777	at least 8 weeks
T52	Procedure 781 799	therapeutic dosing
T53	Multiplier 811 827	at least 4 weeks
T54	Procedure 831 844	stable dosing
R26	Has_multiplier Arg1:T54 Arg2:T53	
R27	Has_multiplier Arg1:T52 Arg2:T51	
T55	Temporal 880 888	previous
T56	Procedure 889 892;925 932	CBT therapy
T57	Observation 896 912	subject declines
T58	Temporal 913 920	current
T59	Procedure 921 932	CBT therapy
R28	Has_temporal Arg1:T56 Arg2:T55	
T60	Condition 865 874	remission
T61	Negation 846 853	Failure
R29	Has_negation Arg1:T60 Arg2:T61	
R30	Has_temporal Arg1:T59 Arg2:T58	
R31	AND Arg1:T57 Arg2:T59	
*	OR T56 T57
T62	Scope 880 932	previous CBT or subject declines current CBT therapy
R32	Has_scope Arg1:T60 Arg2:T62	
T63	Scope 761 844	at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing
T64	Scope 672 751	at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA)
R33	Has_scope Arg1:T64 Arg2:T63	
R34	Has_scope Arg1:T39 Arg2:T64	
R35	Has_qualifier Arg1:T26 Arg2:T25	
R36	Has_scope Arg1:T38 Arg2:T37	
T65	Scope 339 932	DSM-5 criteria for any of the following anxiety disorders: Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder by structured interview (MINI-KID); ADIS Clinical Severity Rating ≥4 (moderately severe) for any of the 4 included anxiety disorders; Failure to achieve remission with at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing; Failure to achieve remission with previous CBT or subject declines current CBT therapy
R37	Has_scope Arg1:T24 Arg2:T65	
A1	Optional T24
T66	Scope 12 315	Meet DSM-5 criteria for Major Depressive Disorder by structured interview (MINI-KID); CDRS-R score >40; Failure to achieve remission with at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing
R38	Has_scope Arg1:T1 Arg2:T66	
A2	Optional T1
T67	Qualifier 934 940	Stable
T68	Drug 941 964	psychiatric medications
T69	Multiplier 934 940;969 974	Stable doses
T70	Temporal 975 1008	for the month prior to enrollment
T71	Reference_point 998 1008	enrollment
R39	Has_index Arg1:T70 Arg2:T71	
R40	Has_temporal Arg1:T68 Arg2:T70	
R41	Has_multiplier Arg1:T68 Arg2:T69	
R42	Has_qualifier Arg1:T68 Arg2:T67	
T72	Non-representable 1010 1071	Subjects may continue to engage in any ongoing psychotherapy.
T73	Condition 1087 1109	neurologically healthy
T74	Condition 1073 1082;1102 1109	Medically healthy
T75	Procedure 1126 1146	physical examination
T76	Observation 1151 1166	medical history
T77	Scope 1126 1166	physical examination and medical history
T78	Scope 1073 1109	Medically and neurologically healthy
R43	Has_scope Arg1:T78 Arg2:T77	
T79	Person 1169 1176	Parents
T80	Observation 1185 1217	provide written informed consent
T81	Person 1222 1233	adolescents
T82	Observation 1252 1266	provide assent
R44	Has_context Arg1:T79 Arg2:T80	
A3	Optional T81
R45	Has_context Arg1:T81 Arg2:T82	
